Gennex Laboratories

12.25
+0.24
(2.00%)
Market Cap
278.66 Cr
EPS
0.61
PE Ratio
14.65
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
29.00
52 Week Low
11.41
PB Ratio
1.56
Debt to Equity
0.03
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,723.50
#1 4,13,525.38
35.22
#1 49,887.20
12.06
#1 9,648
13.77
54.16
5,776.40
1,53,345.27
75.20
8,184.00
0.89
1,600
#1 64.53
56.90
1,451.75
1,17,245.50
24.00
26,520.70
14.17
4,155
47.38
51.80
3,215.15
1,08,815.29
58.64
10,785.70
11.59
1,656
13.54
59.74
2,421.20
99,893.51
49.78
10,615.60
19.57
1,942
-16.38
59.91
1,149.70
95,937.33
#1 18.06
28,905.40
12.36
5,578
1.69
47.74
2,000.00
91,308.19
32.14
20,141.50
#1 19.94
1,936
38.82
47.45
883.85
88,935.99
19.77
19,831.50
13.82
3,831
29.92
42.86
1,154.30
67,041.93
19.21
29,559.20
17.55
3,169
-10.04
53.81
30,753.15
65,348.30
48.70
6,097.20
10.80
1,201
16.01
55.29
Growth Rate
Revenue Growth
31.61 %
Net Income Growth
169.39 %
Cash Flow Change
-297.17 %
ROE
31.28 %
ROCE
37.23 %
EBITDA Margin (Avg.)
92.60 %

Quarterly Financial Results

Quarterly Financials
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
8
11
12
14
10
11
15
21
16
14
15
12
13
15
15
16
10
14
17
20
14
19
14
19
17
18
19
34
28
32
38
Expenses
7
10
11
14
9
10
14
19
15
13
14
11
12
14
14
14
9
12
15
19
13
18
13
17
11
12
17
29
24
26
33
EBITDA
1
1
1
1
1
1
1
2
2
1
1
1
1
2
2
3
2
2
1
1
1
1
1
1
5
5
3
4
4
6
5
Operating Profit %
9 %
8 %
7 %
-1 %
8 %
7 %
8 %
7 %
8 %
7 %
4 %
5 %
6 %
10 %
11 %
16 %
16 %
13 %
7 %
4 %
6 %
7 %
8 %
7 %
31 %
29 %
13 %
13 %
15 %
18 %
13 %
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
1
1
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
0
1
Profit Before Tax
0
0
1
0
1
1
1
1
1
1
0
0
1
1
2
2
1
2
1
1
1
1
2
3
4
4
4
5
6
6
6
Tax
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
Net Profit
0
0
0
-0
1
1
1
0
1
1
0
0
0
1
1
2
1
1
1
1
1
1
1
2
3
3
3
5
5
5
5
EPS in ₹
0.03
0.03
0.02
-0.02
0.03
0.04
0.07
0.02
0.06
0.04
0.02
0.02
0.03
0.07
0.10
0.15
0.08
0.09
0.06
0.10
0.06
0.08
0.07
0.19
0.16
0.16
0.16
0.16
0.19
0.21
0.22

Balance Sheet

Balance Sheet
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
49
51
52
57
59
68
132
230
Fixed Assets
16
16
16
15
14
14
74
56
Current Assets
26
28
29
35
38
47
49
162
Capital Work in Progress
0
0
0
0
0
0
0
2
Investments
7
7
7
7
7
7
0
0
Other Assets
27
28
29
35
38
48
59
172
Total Liabilities
49
51
52
57
59
68
132
230
Current Liabilities
17
18
17
21
19
24
30
40
Non Current Liabilities
1
1
1
0
0
0
16
13
Total Equity
31
32
34
36
40
44
87
177
Reserve & Surplus
18
19
21
23
27
31
62
142
Share Capital
13
13
13
13
13
13
18
23

Cash Flow

Cash Flow
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-0
0
2
-2
0
8
6
46
Investing Activities
-1
-1
-1
-0
0
-3
-38
19
Operating Activities
-0
3
2
-2
-1
12
24
-47
Financing Activities
1
-2
1
-0
2
-2
21
74

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Aug 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Feb 2024
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
22.05 %
22.05 %
22.05 %
22.05 %
22.05 %
22.05 %
23.38 %
23.38 %
23.38 %
23.38 %
23.38 %
23.60 %
23.60 %
18.42 %
18.42 %
18.42 %
18.42 %
18.42 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
63.16 %
70.52 %
74.55 %
73.70 %
75.16 %
74.50 %
61.37 %
63.41 %
63.41 %
63.27 %
60.60 %
58.05 %
60.22 %
58.81 %
60.42 %
61.74 %
59.00 %
60.53 %
Others
14.79 %
7.43 %
3.40 %
4.25 %
2.79 %
3.45 %
15.25 %
13.21 %
13.21 %
13.35 %
16.02 %
18.34 %
16.17 %
22.78 %
21.16 %
19.85 %
22.59 %
21.05 %
No of Share Holders
20,806
36,243
46,380
50,052
56,689
57,877
57,603
59,172
58,248
55,609
52,981
50,988
69,723
69,750
83,996
87,820
90,236
92,506

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Announcements

Closure of Trading Window2 days ago
Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.4 days ago
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.4 days ago
Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.7 days ago
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 20117 days ago
Integrated Filing (Financial)Mar 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 17, 2025
Unaudited Financial Results For Quarter And Nine Months Ended December 31 2024Feb 14, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Of Gennex Laboratories LimitedFeb 14, 2025
Statement Of Deviation Or Variation In The Use Of Proceeds Pursuant To Regulations 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations. - Scrip Code: 531739/GENNEX Feb 14, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorFeb 14, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 10, 2025
Board Meeting Intimation for Unaudited Financial Results For The Quarter And Nine Months Ended 31St December 2024Feb 03, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 29, 2025
Closure of Trading WindowDec 27, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 16, 2024
Financial Results For The Quarter And Half Year Ended September 30, 2024Nov 14, 2024
Board Meeting Outcome for Outcome Of The Board Meeting Of Gennex Laboratories Limited - Scrip Code: 531739/GENNEXNov 14, 2024
Intimation Of Reconstitution Of Audit Committee, Stakeholders Relationship Committee And Nomination And Remuneration Committee Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations, 2015.Nov 14, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementNov 14, 2024
Statement Of Deviation Or Variation In The Use Of Proceeds Pursuant To Regulations 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations. - Scrip Code: 531739/GENNEXNov 14, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 13, 2024
Board Meeting Intimation for Consideration And Approval Of Unaudited (Standalone And Consolidated) Financial Results Of The Company For The Quarter And Half Year Ended On September 30, 2024Nov 05, 2024
Grant Of Test License By Drugs Control Administration, Government Of Andhra Pradesh To Our Subsidiary Company, Deccan Remedies LimitedOct 28, 2024
Approval Of Additional Products From Drug Control Administration, Government Of Andhra Pradesh For Our Subsidiary Company, Deccan Remedies LimitedOct 28, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 25, 2024
Announcement under Regulation 30 (LODR)-Resignation of DirectorOct 04, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportOct 01, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementOct 01, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2024
Closure of Trading WindowSep 25, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateSep 11, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementSep 09, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 09, 2024
Reg. 34 (1) Annual Report.Sep 07, 2024
Intimation Of Book Closure Of Gennex Laboratories Limited - BSE Script Code: 531739Sep 06, 2024
Board Meeting Outcome for Outcome Of The Board Meeting Held On September 06, 2024 Of Gennex Laboratories Limited- Scrip Code: 531739/GENNEXSep 06, 2024
Board Meeting Intimation for Deciding The Conduct Of 39Th AGM For The Year Ended March 31, 2024Aug 28, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 17, 2024
Statement Of Deviation Or Variation In The Use Of Proceeds Pursuant To Regulations 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations. - Scrip Code: 531739/GENNEXAug 14, 2024
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)Aug 14, 2024
Board Meeting Outcome for Outcome Of The Board Meeting Of Gennex Laboratories Limited Held On August 14, 2024Aug 14, 2024
Financial Results For Quarter Ended June 30, 2024Aug 14, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 07, 2024
Board Meeting Intimation for Approval Of The Un-Audited Financial Results Of The Company For The Quarter Ended 30.06.2024.Aug 05, 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Jul 31, 2024
Closure of Trading WindowJun 28, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 01, 2024
Financial Results For The Year Ended March 31, 2024May 30, 2024

Technical Indicators

RSI(14)
Neutral
37.73
ATR(14)
Less Volatile
1.08
STOCH(9,6)
Neutral
38.15
STOCH RSI(14)
Oversold
1.15
MACD(12,26)
Bearish
-0.13
ADX(14)
Weak Trend
21.63
UO(9)
Bearish
30.48
ROC(12)
Downtrend And Accelerating
-6.03
WillR(14)
Oversold
-90.56